Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abiraterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 17/20 | 0.90 |
| ▸ | AR known ✓ | P10275 | 1/20 | 0.74 |
| ▸ | CYP21A2 | P08686 | 8/20 | 0.90 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.90 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CDK8 | P49336 | 3/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abiraterone SCHEMBL16429887 | 1.00 | CYP17A1 (0.90) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL15881070 | 1.00 | CYP17A1 (0.90) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL15414434 | 1.00 | CYP17A1 (0.90) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL16429803 | 1.00 | CYP17A1 (0.90) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL16429801 | 0.99 | CYP17A1 (0.89) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL15757705 | 0.98 | CYP17A1 (0.87) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL17267903 | 0.97 | CYP17A1 (0.85) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL1961219 | 0.96 | CYP17A1 (0.84) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL23924960 | 0.95 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL13272100 | 0.95 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14065 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4467200-B1 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | CONSTELLATION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-120504685-B | Prodrug structure with ROS signal response performance, and preparation method and application thereof | Rehabilitation University (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-4744666-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4743497-A2 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | Janux Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260132215-A1 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | Janux Therapeutics, Inc. | 2026-05-14 | — | — | US | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260125761-A1 | PREDICTION OF AN OUTCOME OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IN A PROSTATE CANCER SUBJECT | KONINKLIJKE PHILIPS NV (NL) | 2026-05-07 | — | — | US | claimed |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2026-04-30 | — | — | US | claimed |
| WO-2008127290-A9 | ALGINATE AND ALGINATE LYASE COMPOSITIONS AND METHODS OF USE | UNIV JOHNS HOPKINS (US) | 2008-12-24 | — | — | WO | claimed |
| WO-2008127290-A2 | ALGINATE AND ALGINATE LYASE COMPOSITIONS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-10-23 | — | — | WO | claimed |
| EP-1909812-A2 | SMALL COMPOUNDS THAT CORRECT PROTEIN MISFOLDING AND USES THEREOF | University of Florida Research Foundation, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2008024484-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | COUGAR BIOTECHNOLOGY, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008024485-A2 | METHODS FOR TREATING CANCER COMPRISING THE ADMINISTRATION OF A VITAMIN D COMPOUND AND AN ADDITIONAL THERAPEUTIC AGENT | COUGAR BIOTECHNOLOGY, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080051380-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | INSTITUTE OF CANCER RESEARCH (GB) | 2008-02-28 | — | — | US | claimed |
| US-20080051375-A1 | METHODS FOR TREATING CANCER COMPRISING THE ADMINISTRATION OF A VITAMIN D COMPOUND AND AN ADDITIONAL THERAPEUTIC AGENT, AND COMPOSITIONS CONTAINING THE SAME | COUGAR BIOTECHNOLOGY, INC. | 2008-02-28 | — | — | US | claimed |
| EP-1874118-A2 | MATERIALS AND METHODS FOR ENHANCED DEGRADATION OF MUTANT PROTEINS ASSOCIATED WITH HUMAN DISEASE | University of Florida (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2007014327-A2 | SMALL COMPOUNDS THAT CORRECT PROTEIN MISFOLDING AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-02-01 | — | — | WO | claimed |
| WO-2006116716-A2 | MATERIALS AND METHODS FOR ENHANCED DEGRADATION OF MUTANT PROTEINS ASSOCIATED WITH HUMAN DISEASE | UNIVERSITY OF FLORIDA (US) | 2006-11-02 | — | — | WO | claimed |